AUTORIZAŢIE DE PUNERE PE PIAŢĂ NR. 4747/2012/01-02-03 Anexa 1 Prospect PROSPECT: INFORMAŢII PENTRU UTILIZATOR Acid ibandroni
![Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial - The Lancet Oncology Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/2021742717/2041575575/gr6.jpg)
Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial - The Lancet Oncology
A process for the preparation of alkyl- and aryl-diphosphonic acids and salts thereof - European Patent Office - EP 2206717 A1
![PDF) The Effectiveness of Zoledronic Acid and Ibandronic Acid in Delaying Skeletal-Related Events in Multiple Myeloma in Indonesia PDF) The Effectiveness of Zoledronic Acid and Ibandronic Acid in Delaying Skeletal-Related Events in Multiple Myeloma in Indonesia](https://i1.rgstatic.net/publication/348241531_The_Effectiveness_of_Zoledronic_Acid_and_Ibandronic_Acid_in_Delaying_Skeletal-Related_Events_in_Multiple_Myeloma_in_Indonesia/links/5ff5372192851c13feefdd7e/largepreview.png)